MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opp

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list.

TheFly reported on June 22 that Clear Street maintained its Buy rating and $70 price target on MLTX. The firm highlighted SLK's potential in hidradenitis suppurativa following the company's investor event focused on the therapy's development and commercialization strategy. Clear Street noted that SLK's profile in HS remains highly competitive and could support a significant commercial opportunity. The firm also stated that the Biologics License Application submission remains expected by September 30, with management continuing to view the possibility of priority review.

Moreover, on June 23, MoonLake Immunotherapeutics (NASDAQ:MLTX) announced the pricing of its underwritten public offering, including 9 million Class A ordinary shares at $20.00 per share and pre-funded warrants for up to 1 million additional shares at $19.9999 per warrant. The offering is expected to generate approximately $200 million in gross proceeds before fees and expenses. MLTX also provided underwriters with a 30-day option to purch

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-mltx-outlook-strengthens-132211625.html)